Self-Injection of Contraception is Feasible, Acceptable in Uganda
Self-injection of the contraceptive Sayana® Press is both feasible and highly acceptable among women participating in the first such research study conducted in sub-Saharan Africa, according to results published online by the journal Contraception.
Sayana Press is an all-in-one injectable contraceptive that puts control of women’s health in their hands. It is a subcutaneous formulation of the widely used injectable contraceptive depot medroxyprogesterone acetate (DMPA-SC) delivered in the PATH-developed Uniject™ injection system.
“This pioneering research is important not only for the women of Uganda, but for all women,” says Professor Dr. Anthony K. Mbonye, Acting Director General, Health Services, Ministry of Health, and co-investigator of the study. “The evidence that women can self-inject safely and successfully can help inform family planning program decision-making in countries around the world.”
In low- and middle-income regions of the world, nearly 225 million women want to plan their pregnancies but don’t have access to a method that meets the reality of their lives. Expanding access to new contraceptive options such as Sayana Press can improve health and save lives by allowing women to delay or space their births.
- Health Care